BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 18, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lixisenatide: Phase III data

Top-line data from the double-blind, international Phase III GetGoal-S trial in 859 Type II diabetics inadequately controlled by sulfonylureas with or without metformin showed that once-daily lixisenatide met the primary endpoint of significantly reducing HbA1c from baseline to week 24 vs. placebo. Specifically, lixisenatide reduced HbA1c by 0.74% compared to placebo (p<0.0001). Lixisenatide also met...

Read the full 253 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >